UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent advances in the management of renal cell carcinoma

F1000 research, 2016, Vol.5, p.391

2016

Volltextzugriff (PDF)

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

Neoplasia (New York, N.Y.), 2013-01, Vol.15 (1), p.1

2013

Volltextzugriff (PDF)

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Journal of clinical oncology, 2024-03, Vol.42 (7), p.842-851

2024

Volltextzugriff (PDF)

Using circulating tumor cells to advance precision medicine in prostate cancer

Journal of cancer metastasis and treatment, 2017-01, Vol.3 (9), p.190-205

2017

Volltextzugriff (PDF)

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al

Journal of clinical oncology, 2019-08, Vol.37 (24), p.2184-2186

2019

Volltextzugriff (PDF)

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Clinical cancer research, 2019-03, Vol.25 (6), p.1880-1888

2019

Volltextzugriff (PDF)

Novel targets in altered tumour metabolism in kidney cancer

Nature reviews. Urology, 2015-08, Vol.12 (8), p.428-429

2015

Volltextzugriff (PDF)

MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177 LU-J591) FOR MCRPC

The Journal of urology, 2016-04, Vol.195 (4), p.e680-e680

2016

Volltextzugriff (PDF)

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Clinical cancer research, 2015-12, Vol.21 (23), p.5277-5285

2015

Volltextzugriff (PDF)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Journal of medical case reports, 2009-09, Vol.3 (1), p.9110-9110

2009

Volltextzugriff (PDF)

Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

Clinical cancer research, 2005-10, Vol.11 (19), p.7195s-7200s

2005

Volltextzugriff (PDF)

Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15600-e15600

2013

Volltextzugriff (PDF)

952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591

The Journal of urology, 2012-04, Vol.187 (4), p.e387-e388

2012

Volltextzugriff (PDF)

Correction: Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device

PloS one, 2012-07, Vol.7 (7)

2012

Volltextzugriff (PDF)

Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent

AMIA Summits on Translational Science proceedings, 2019, Vol.2019, p.163-172

2019

Volltextzugriff (PDF)

Cancer therapies that are gone with the Wnt: Wnt signaling in prostate cancer cells may contribute to escape from androgen receptor–targeted therapies

Science (American Association for the Advancement of Science), 2015-09, Vol.349 (6254), p.1283-1284

2015

Volltextzugriff (PDF)

Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma

Journal of immunotherapy (1997), 2007-09, Vol.30 (6), p.655-662

2007

Volltextzugriff (PDF)

A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS248-TPS248

2024

Volltextzugriff (PDF)

Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.161-161

2024

Volltextzugriff (PDF)

Advanced renal cell carcinoma

Current treatment options in oncology, 2001-09, Vol.2 (5), p.437-445

2001

Volltextzugriff (PDF)

Surveillance of urothelial carcinoma

Cancer, 2009-04, Vol.115 (7), p.1435-1447

2009

Volltextzugriff (PDF)

Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.217-217

2024

Volltextzugriff (PDF)

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5098-TPS5098

2023

Volltextzugriff (PDF)

Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177 Lu or 111 In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.LBA21-LBA21

2023

Volltextzugriff (PDF)

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5060-5060

2023

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(203)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Englisch
(212)
Japanisch
(5)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recent advances in the management of renal cell carcinoma

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591

Using circulating tumor cells to advance precision medicine in prostate cancer

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Novel targets in altered tumour metabolism in kidney cancer

MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (177 LU-J591) FOR MCRPC

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity

Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents

952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591

Correction: Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device

Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent

Cancer therapies that are gone with the Wnt: Wnt signaling in prostate cancer cells may contribute to escape from androgen receptor–targeted therapies

Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma

A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC)

Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector

Advanced renal cell carcinoma

Surveillance of urothelial carcinoma

Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza)

Whole-food plant-based diet (WFPBD) to control weight and metabo-inflammation in overweight/obese men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial

Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177 Lu or 111 In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC)

The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide

Aktive Filter

Suchergebnisse filtern